Evidence map›Paper›PMID 40531397›Full record

ReviewJapanese journal of radiology2025

Recent advances in drug treatment for prostate cancer.

Kotaro Suzuki, Naohiro Fujimoto, Masaki Shiota, Satoru Kawakami, Takahiro Kimura, Kohei Hashimoto, Takeo Kosaka, Hideaki Miyake, Hiroji Uemura

Abstract readReview
PubMed Publisher
In one paragraph

Review in Japanese journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Observational
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kotaro SuzukiDivision of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan. pikataro1012@gmail.com.ORCID http://orcid.org/0000-0003-4589-9251
Naohiro FujimotoDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Satoru KawakamiDepartment of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Kohei HashimotoDepartment of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Takeo KosakaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Hideaki MiyakeDivision of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Hiroji UemuraDepartment of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the advent of androgen receptor signaling inhibitors (ARSI), chemotherapy, poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi), and radioligand therapy targeting prostate-specific membrane antigen (PSMA), survival outcomes in metastatic prostate cancer (PCa) have dramatically improved over the past two decades. In addition, recent advancements in imaging modalities and genomic testing have significantly impacted diagnostic and therapeutic strategies for advanced PCa. However, with increasing drug options and the emergence of new disease concepts for non-metastatic castration-resistant prostate cancer (nmCRPC), treatment strategies for advanced PCa have become more complicated and uncertain. In addition, the emergence of aggressive PCa variants, including treatment-related neuroendocrine PCa (t-NEPC), is another clinical concern in the era of upfront and long-term use of potent ARSIs. The aim of this review is to summarize the latest drug treatment strategies and clinical concerns in the management of advanced PCa in Japan, based on the Japanese Clinical Practice Guidelines for Prostate Cancer published in 2023.

Indexed as

Androgen Receptor AntagonistsAntineoplastic AgentsProstatic NeoplasmsHumansJapanMalePoly(ADP-ribose) Polymerase InhibitorsAndrogen Receptor AntagonistsAntineoplastic AgentsPoly(ADP-ribose) Polymerase InhibitorsChemotherapyHormonal therapyMetastasisProstate cancer

Identifiers

PMID40531397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.